Overview of Recent Financial Performance
In a significant update from 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP), the company announced an increase in net product revenue for the third quarter of 2025. The revenue soared to $438 thousand, marking an impressive 223% rise compared to the same time last year. Despite this growth, the company experienced challenges with a gross loss that deepened from $24 thousand to $100 thousand.
Financial Highlights for Q3 2025
During the third quarter of 2025, several key financial metrics highlighted the company's evolving landscape:
- The volume of ARAKODA® pharmacy deliveries rose by 14%, reflecting a growth from 1,319 boxes in Q3 2024 to 1,505 boxes in Q3 2025.
- The company faced a significant gross loss of about $100 thousand, attributed primarily to a one-time inventory write-off linked to validation lots that will not meet supply chain acceptance past early 2026. However, new lots with adequate shelf-life are currently in production and are anticipated to integrate into the supply chain soon.
- Operating expenses reached approximately $2.32 million, an uptick from $2.16 million in the previous year. This increase was significantly influenced by added advertising and promotional expenditures which accounted for $367 thousand.
- The net loss attributable to common shareholders was approximately $2.44 million, translating to a loss of ($0.66) per share. In the same quarter last year, the loss was roughly $2.27 million, or ($4.65) per share.
Strategic Business Developments
Aside from financial performance, 60 Degrees Pharmaceuticals has made considerable strides in its business initiatives during this quarter:
- On July 14, the company expressed its intent to pursue a Minor Use Minor Species (MUMS) designation from the FDA to treat acute canine babesiosis following an extensive analysis of their existing data.
- A nationwide survey involving 6,000 patients was conducted, leading to a determination of the total addressable market (TAM) for Babesiosis treatment, estimated at up to $1.1 billion leading up to patent expiration in 2035.
- A sponsored research agreement with Tulane University was established on July 17 to explore the efficacy of tafenoquine against Borrelia (Lyme) and Bartonella bacteria.
- Furthermore, on August 19, a partnership with the Icahn School of Medicine at Mount Sinai was announced, focused on a Phase II clinical study evaluating tafenoquine in treating chronic babesiosis.
About 60 Degrees Pharmaceuticals, Inc.
Founded in 2010, 60 Degrees Pharmaceuticals, Inc. is at the forefront of developing new treatments for vector-borne diseases. The company celebrated the FDA approval of ARAKODA® (tafenoquine) in 2018, which is aimed at the prevention of malaria. Collaborating with esteemed research organizations across the U.S., Australia, and Singapore underscores its commitment to advancing pharmaceutical science. Significant funding support has come from the U.S. Department of Defense alongside private investors such as Knight Therapeutics Inc. The headquarters are located in Washington D.C., with a major subsidiary positioned in Australia.
Frequently Asked Questions
What financial results did 60 Degrees Pharmaceuticals report for Q3 2025?
The company reported a net product revenue increase of 223% year-over-year, amounting to $438 thousand, alongside a gross loss of approximately $100 thousand.
What are the key business developments from 60 Degrees Pharmaceuticals?
The company announced its intention to pursue MUMS designation for canine babesiosis, a significant market analysis indicating a TAM of up to $1.1 billion, and established research partnerships for ongoing clinical studies.
How did operating expenses change in Q3 2025?
Operating expenses increased to around $2.32 million due to a rise in advertising and sales promotion costs compared to the previous year.
What is ARAKODA® and its significance?
ARAKODA® (tafenoquine) is the lead product from 60 Degrees Pharmaceuticals, approved for malaria prevention. It represents a key achievement for the company in developing treatments for vector-borne diseases.
Who should I contact for media and investor inquiries regarding 60 Degrees Pharmaceuticals?
For media inquiries, contact Sheila A. Burke at SheilaBurke-consultant@60degreespharma.com. For investor inquiries, reach Patrick Gaynes at patrickgaynes@60degreespharma.com.
